Who makes HBI 0201-ESO TCRT?

HBI 0201-ESO TCRT is developed by Hadassah Medical Organization.

What development phase is HBI 0201-ESO TCRT in?

HBI 0201-ESO TCRT is in Phase 1.

Last reviewed 2026-04-19 · How we verify

HBI 0201-ESO TCRT

Hadassah Medical Organization · Phase 1 active Biologic

At a glance

Generic name	HBI 0201-ESO TCRT
Sponsor	Hadassah Medical Organization
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

HBI 0201-ESO TCRT CI brief — competitive landscape report
HBI 0201-ESO TCRT updates RSS · CI watch RSS
Hadassah Medical Organization portfolio CI